Sumaiya Cassim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sumaiya Cassim has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Dharshnee Rama Chetty
University of Cape Town
2 shared publications - Estelle Verburgh
Division of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
2 shared publications - Jenna Bailey
Division of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
2 shared publications - Katherine Antel
Medical University of South Carolina
2 shared publications - Zainab Mohamed
University of Cape Town
2 shared publications - Amsha Ramburan
Division of Anatomical Pathology, Department of Pathology, Faculty of Health Sciences, University of Cape Town and National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa
1 shared publication
Latest Publications
- Open Access
- 2 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Real-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards
Background: Lymphoma real-world observational data and accurate diagnostic systems are lacking in low-resource HIV-endemic settings. We established a new lymphoma registry to generate internationally comparable, clinically validated data, with up-to-date disease classification. We also describe our findings on aggressive B-cell lymphoma. Methods: The descriptive retrospective cohort included patients ≥ 13 years of age newly diagnosed with lymphoma from 2005 to 2020. Patients were enrolled at a single site in a registry with hierarchical groupings to capture, interrogate, and subtype lymphoma diagnoses. These were standardised on the most recent version of the World Health Organisation Classification of Haematolymphoid Tumours (WHO-HAEM5) and correlated with the novel International Consensus Classification of mature lymphoid neoplasms (ICC). Differences due to nomenclature and diagnostic category were annotated. Results: The cohort consisted of 2354 incident lymphoma cases; 1891 (80.3%) non-Hodgkin lymphoma and 463 (19.7%) Hodgkin lymphoma (HL). Twenty-one lymphoma NOS cases were excluded due to inadequate specimen for standardised subclassification. Overall reclassification according to WHO-HAEM5 was 25.8% ( n = 608). Notable nomenclature differences between WHO-HAEM5 and ICC included 44 (1.9%) transformations of indolent B-cell lymphomas; also 857 (36.4%) lymphoid proliferations and lymphomas associated with immune deficiency/dysregulation due to HIV (33.1%) and EBV (31.8%). EBV-association was highest among HL cases, of which 77 (50.3%) were HIV reactive. Conclusion: We report here the impact of adopting international lymphoma classification standards in an HIV-endemic setting. Our findings highlight the persistent prevalence of large B-cell lymphoma, raise concern around inadequate HIV suppression as a potential ongoing driver of disease in our setting, and provide further evidence for EBV-associated HL as a distinct subtype.
- 2 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessReal-world lymphoma cohort in an HIV-endemic setting: cohort design, epidemiological features and impact of implementing novel classification standards
Background: Lymphoma real-world observational data and accurate diagnostic systems are lacking in low-resource HIV-endemic settings. We established a new lymphoma registry to generate internationally comparable, clinically validated data, with up-to-date disease classification. We also describe our findings on aggressive B-cell lymphoma. Methods: The descriptive retrospective cohort included patients ≥ 13 years of age newly diagnosed with lymphoma from 2005 to 2020. Patients were enrolled at a single site in a registry with hierarchical groupings to capture, interrogate, and subtype lymphoma diagnoses. These were standardised on the most recent version of the World Health Organisation Classification of Haematolymphoid Tumours (WHO-HAEM5) and correlated with the novel International Consensus Classification of mature lymphoid neoplasms (ICC). Differences due to nomenclature and diagnostic category were annotated. Results: The cohort consisted of 2354 incident lymphoma cases; 1891 (80.3%) non-Hodgkin lymphoma and 463 (19.7%) Hodgkin lymphoma (HL). Twenty-one lymphoma NOS cases were excluded due to inadequate specimen for standardised subclassification. Overall reclassification according to WHO-HAEM5 was 25.8% ( n = 608). Notable nomenclature differences between WHO-HAEM5 and ICC included 44 (1.9%) transformations of indolent B-cell lymphomas; also 857 (36.4%) lymphoid proliferations and lymphomas associated with immune deficiency/dysregulation due to HIV (33.1%) and EBV (31.8%). EBV-association was highest among HL cases, of which 77 (50.3%) were HIV reactive. Conclusion: We report here the impact of adopting international lymphoma classification standards in an HIV-endemic setting. Our findings highlight the persistent prevalence of large B-cell lymphoma, raise concern around inadequate HIV suppression as a potential ongoing driver of disease in our setting, and provide further evidence for EBV-associated HL as a distinct subtype.
- Open Access
- 30 October 2025
- Published by Elsevier in Next Research
- Vol. 2 (4)
An in-depth analysis of AI-generated scientific review articles and its potential implications on the future of medical journal publications
- 30 October 2025
- Published by Elsevier in Next Research
- Vol. 2 (4)
Open AccessAn in-depth analysis of AI-generated scientific review articles and its potential implications on the future of medical journal publications
- Open Access
- 23 December 2023
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 2 (1) , 11
Comparison of the World Health Organisation and International Consensus Classification of haematolymphoid tumours
Background: The World Health Organization has updated its classification of haematolymphoid tumours to the new 5th edition. The International Consensus Classification is another group that has developed a separate classification system with similar but conflicting approaches. This led to a debate among haematologists about which classification system is more appropriate for clinical use. This article examines and compares these contrasting and concurring classifications, and provides insight into the utility of each system. Methods: Journal articles pertaining to WHO-HAEM4R, WHO-HAEM5 and ICC were searched for using the MEDLINE database, from November 2022 to November 2023. Original research articles and reviews were selected to compile this review. Results: The classification systems share many similarities with minor name changes and subgrouping. There are few instances where diagnostic grouping differs between the classifications, which could have clinical implications regarding treatment and enrolment in clinical trials. Conclusion: There is universal agreement about the need for objective criteria for the classification of haematolymphoid tumours. As a result, there have been considerable strides in the classification with regard to morphologic, immunophenotypic, molecular and cytogenetic characterisation. It is reassuring to have a stepwise approach to diagnosis, allowing developing countries to make appropriate diagnoses. Contribution: Harmonisation is needed for a universal diagnostic system for the benefit of the patient. Both classification systems have merit and either could be adopted by individual institutions at present. The authors appeal for interim advocacy measures to assure access to the specific diagnostic investigations in poorly resourced societies, pending more permanent and sustainable access.
- 23 December 2023
- Published by AOSIS in Journal of the Colleges of Medicine of South Africa
- Vol. 2 (1) , 11
Open AccessComparison of the World Health Organisation and International Consensus Classification of haematolymphoid tumours
Background: The World Health Organization has updated its classification of haematolymphoid tumours to the new 5th edition. The International Consensus Classification is another group that has developed a separate classification system with similar but conflicting approaches. This led to a debate among haematologists about which classification system is more appropriate for clinical use. This article examines and compares these contrasting and concurring classifications, and provides insight into the utility of each system. Methods: Journal articles pertaining to WHO-HAEM4R, WHO-HAEM5 and ICC were searched for using the MEDLINE database, from November 2022 to November 2023. Original research articles and reviews were selected to compile this review. Results: The classification systems share many similarities with minor name changes and subgrouping. There are few instances where diagnostic grouping differs between the classifications, which could have clinical implications regarding treatment and enrolment in clinical trials. Conclusion: There is universal agreement about the need for objective criteria for the classification of haematolymphoid tumours. As a result, there have been considerable strides in the classification with regard to morphologic, immunophenotypic, molecular and cytogenetic characterisation. It is reassuring to have a stepwise approach to diagnosis, allowing developing countries to make appropriate diagnoses. Contribution: Harmonisation is needed for a universal diagnostic system for the benefit of the patient. Both classification systems have merit and either could be adopted by individual institutions at present. The authors appeal for interim advocacy measures to assure access to the specific diagnostic investigations in poorly resourced societies, pending more permanent and sustainable access.